Deerfield, Ill. - April 17, 2015
Today, Baxter International joins the World Federation of Hemophilia (WFH) and its partners in the global hemophilia community to recognize World Hemophilia Day, an annual observation intended to help raise awareness of hemophilia and other bleeding disorders.
This year, the WFH is educating the global community about the importance of building a "family of support" for people living with bleeding disorders around the world. The organization is providing resources and information to raise a dialogue about the extensive care, support and advocacy that is provided by extended family and friends, caregivers and loved ones.
"Baxter BioScience continues to play a leading role in advancing the quality and availability of care for bleeding disorders worldwide, and we have designed our patient support programs to consider the specific needs and contributions of caregivers, families and friends," said Brian Goff, leader of Baxter's global hemophilia organization. "As we celebrate our collective progress on World Hemophilia Day, we recognize the need for continued education and awareness as we continue our pursuit of a Bleed Free World."
In recent years, Baxter has showcased progress in advancing care for the hemophilia community through a number of newly approved therapies and new indications of existing treatments. We continue to build our pipeline, with a focus on introducing new options that meet individual patient needs across a range of blood disorders.
About Baxter in Hemophilia
Baxter has more than 60 years of experience in hemophilia and has introduced a number of therapeutic firsts for hemophilia patients. Baxter has one of the broadest portfolio of hemophilia treatments in the industry and is able to meet individual therapy choices, providing a range of options at each treatment stage. The company's work focuses on optimizing hemophilia care and improving the lives of people worldwide living with bleeding disorders.
About Baxter BioScience
Baxter BioScience is a leading provider of therapeutic treatments that save, sustain and improve the lives of people with rare conditions, chronic diseases or limited treatment options. Supported by advanced technical and manufacturing expertise, Baxter BioScience has a broad pipeline built on a legacy of innovation in bleeding disorders and immunology and is expanding to address emerging opportunities in niche areas of oncology as well as technology platforms such as biosimilars.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.